For research use only. Not for therapeutic Use.
NHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease[1].
| Catalog Number | I011176 |
| CAS Number | 1269802-97-2 |
| Synonyms | methyl 1-hydroxy-6-phenyl-4-(trifluoromethyl)indole-2-carboxylate |
| Molecular Formula | C17H12F3NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H12F3NO3/c1-24-16(22)15-9-12-13(17(18,19)20)7-11(8-14(12)21(15)23)10-5-3-2-4-6-10/h2-9,23H,1H3 |
| InChIKey | YPPFWRWCZNXINO-UHFFFAOYSA-N |
| SMILES | COC(=O)C1=CC2=C(C=C(C=C2N1O)C3=CC=CC=C3)C(F)(F)F |
| Reference | [1]. Granchi C, et al. Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds. Org Biomol Chem. 2013;11(38):6588-6596. |
